ALTS
ALT5 SigmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALTS
Alt5 Sigma Corporation
Passively tracked the Morningstar diversified alternatives index
325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119
--
ALT5 Sigma Corporation was founded in Minnesota in 1983. In 2018, the company was re-registered in Nevada. The company is committed to being a clinical-stage pharmaceutical company dedicated to finding treatments for conditions that cause severe pain and bringing drugs with non-addictive analgesic properties to market. One of the company's goals is to reduce the need for dangerous opioid prescriptions by treating underlying conditions that cause severe pain. The company's first drug candidate is a treatment for peripheral arterial disease, which causes severe pain and affects more than 8.5 million people in the United States.
Company Financials
EPS
ALTS has released its 2025 Q2 earnings. EPS was reported at -0.3, versus the expected -0.13, missing expectations. The chart below visualizes how ALTS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALTS has released its 2025 Q2 earnings report, with revenue of 6.38M, reflecting a YoY change of 194.05%, and net profit of -9.12M, showing a YoY change of -1647.54%. The Sankey diagram below clearly presents ALTS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
